中国原发性肝细胞癌放射治疗指南(2020年版)

doi:10.3760/cma.j.cn371439-20201208-00001

摘要/Abstract

中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国原发性肝细胞癌放射治疗指南(2020年版)[J]. 国际肿瘤学杂志, 2021, 48(1): 1-10.

图/表 2

参考文献 68

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338. pmid: 26808342
[2]	Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019,394(10204):1145-1158. DOI: 10.1016/S0140-6736(19)30427-1. doi: 10.1016/S0140-6736(19)30427-1 pmid: 31248666
[3]	欧美同学会医师协会肝胆分会, 中国研究型医院学会分子诊断专委会, 中国临床肿瘤学会肝癌专委会, 等. 肝胆肿瘤分子诊断临床应用专家共识[J]. 中华肝胆外科杂志, 2020,26(2):81-89. DOI: 10.3760/cma.j.issn.1007-8118.2020.02.001.
[4]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020,40(2):121-138. DOI: 10.19538/j.cjps.issn1005-2208.2020.02.01.
[5]	Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging—a systematic review and meta-analysis[J]. Radiology, 2015,275(1):97-109. DOI: 10.1148/radiol.14140690. pmid: 25559230
[6]	Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis[J]. Liver Transpl, 2017,23(12):1505-1518. DOI: 10.1002/lt.24867. pmid: 28886231
[7]	Rao SX, Wang J, Wang J, et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: gadoxetic acid disodium[J]. J Dig Dis, 2019,20(2):54-61. DOI: 10.1111/1751-2980.12707. pmid: 30693659
[8]	Zeng MS, Ye HY, Guo L, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients: a multicenter, open-label, phase Ⅲ study[J]. Hepatobiliary Pancreat Dis Int, 2013,12(6):607-616. DOI: 10.1016/s1499-3872(13)60096-x. doi: 10.1016/s1499-3872(13)60096-x pmid: 24322746
[9]	Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase Ⅲ, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease[J]. Invest Radiol, 2010,45(3):133-141. DOI: 10.1097/RLI.0b013e3181caea5b. pmid: 20098330
[10]	Yoo SH, Choi JY, Jang JW, et al. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma[J]. Ann Surg Oncol, 2013,20(9):2893-2900. DOI: 10.1245/s10434-013-3001-y. pmid: 23649931
[11]	Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology, 2008,47(1):97-104. DOI: 10.1002/hep.21966. doi: 10.1002/hep.21966 pmid: 18069697
[12]	中国临床肿瘤学会. 原发性肝癌诊疗指南[M]. 北京: 人民卫生出版社, 2020.
[13]	Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol, 2014,61(1):82-88. DOI: 10.1016/j.jhep.2014.03.012. doi: 10.1016/j.jhep.2014.04.005
[14]	Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group[J]. Ann Surg, 2013,257(5):929-937. DOI: 10.1097/SLA.0b013e31828329b8. doi: 10.1097/SLA.0b013e31828329b8 pmid: 23426336
[15]	Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma[J]. Semin Radiat Oncol, 2017,27(3):247-255. DOI: 10.1016/j.semradonc.2017.02.002. doi: 10.1016/j.semradonc.2017.02.002 pmid: 28577832
[16]	Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006,243(3):321-328. DOI: 10.1097/01.sla.0000201480.65519.b8. doi: 10.1097/01.sla.0000201480.65519.b8 pmid: 16495695
[17]	Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012,57(4):794-802. DOI: 10.1016/j.jhep.2012.05.007. doi: 10.1016/j.jhep.2012.05.007 pmid: 22634125
[18]	Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma[J]. Br J Surg, 2017,104(13):1775-1784. DOI: 10.1002/bjs.10677. doi: 10.1002/bjs.10677 pmid: 29091283
[19]	Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol, 2013,31(4):426-432. DOI: 10.1200/JCO.2012.42.9936. pmid: 23269991
[20]	Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer, 2010,116(23):5452-5460. DOI: 10.1002/cncr.25314. doi: 10.1002/cncr.25314 pmid: 20672352
[21]	Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2016,40(3):309-314. DOI: 10.1016/j.clinre.2015.07.008. doi: 10.1016/j.clinre.2015.07.008 pmid: 26428660
[22]	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390. DOI: 10.1056/NEJMoa0708857. doi: 10.1056/NEJMoa0708857 pmid: 18650514
[23]	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of so-rafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009,10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. pmid: 19095497
[24]	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. doi: 10.1016/S0140-6736(18)30207-1 pmid: 29433850
[25]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,382(20):1894-1905. DOI: 10.1016/S0140-6736(18)30207-1. doi: 10.1056/NEJMoa1915745 pmid: 32402160
[26]	Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013,31(28):3501-3508. DOI: 10.1200/JCO.2012.44.5643. doi: 10.1200/JCO.2012.44.5643 pmid: 23980077
[27]	Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. doi: 10.1016/S0140-6736(16)32453-9 pmid: 27932229
[28]	El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. doi: 10.1016/S0140-6736(17)31046-2 pmid: 28434648
[29]	Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018,19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. doi: 10.1016/S1470-2045(18)30351-6 pmid: 29875066
[30]	Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with pre-viously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020,21(4):571-580. DOI: 10.1016/S1470-2045(20)30011-5. doi: 10.1016/S1470-2045(20)30011-5 pmid: 32112738
[31]	Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis[J]. Am J Roentgenol Radium Ther Nucl Med, 1965,93:200-208. pmid: 14243011
[32]	Durand-Labrunie J, Baumann AS, Ayav A, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2020,107(1):116-125. DOI: 10.1016/j.ijrobp.2019.12.004. doi: 10.1016/j.ijrobp.2019.12.004 pmid: 32001057
[33]	Takeda A, Sanuki N, Tsurugai Y, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation[J]. Cancer, 2016,122(13):2041-2049. DOI: 10.1002/cncr.30008. doi: 10.1002/cncr.30008 pmid: 27062278
[34]	Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of ste-reotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies[J]. Radiother Oncol, 2019,131:135-144. DOI: 10.1016/j.radonc.2018.12.005. doi: 10.1016/j.radonc.2018.12.005 pmid: 30773180
[35]	Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients[J]. Acta Oncol, 2014,53(3):399-404. DOI: 10.3109/0284186X.2013.820342. doi: 10.3109/0284186X.2013.820342 pmid: 23962244
[36]	Su TS, Liang P, Liang J, et al. Long-term survival analysis of ste-reotactic ablative radiotherapy versus liver resection for small hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2017,98(3):639-646. DOI: 10.1016/j.ijrobp.2017.02.095. doi: 10.1016/j.ijrobp.2017.02.095 pmid: 28581406
[37]	Hara K, Takeda A, Tsurugai Y, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis[J]. Hepatology, 2019,69(6):2533-2545. DOI: 10.1002/hep.30591. doi: 10.1002/hep.30591 pmid: 30805950
[38]	Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma[J]. J Hepatol, 2020,73(1):121-129. DOI: 10.1016/j.jhep.2020.03.005. doi: 10.1016/j.jhep.2020.03.005 pmid: 32165253
[39]	Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Liver Int, 2005,25(6):1189-1196. DOI: 10.1111/j.1478-3231.2005.01170.x. doi: 10.1111/j.1478-3231.2005.01170.x pmid: 16343071
[40]	Kim KH, Kim MS, Chang JS, et al. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma[J]. Liver Int, 2014,34(5):784-794. DOI: 10.1111/liv.12436. doi: 10.1111/liv.12436
[41]	Koom WS, Seong J, Han KH, et al. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas?[J]. Int J Radiat Oncol Biol Phys, 2010,77(5):1433-1440. DOI: 10.1016/j.ijrobp.2009.07.1676. doi: 10.1016/j.ijrobp.2009.07.1676 pmid: 19896779
[42]	Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis[J]. JAMA Oncol, 2015,1(6):756-765. DOI: 10.1001/jamaoncol.2015.2189. doi: 10.1001/jamaoncol.2015.2189 pmid: 26182200
[43]	Chan SL, Chong CC, Chan AW, et al. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016[J]. World J Gastroenterol, 2016,22(32):7289-7300. DOI: 10.3748/wjg.v22.i32.7289. doi: 10.3748/wjg.v22.i32.7289 pmid: 27621575
[44]	Im JH, Yoon SM, Park HC, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area[J]. Liver Int, 2017,37(1):90-100. DOI: 10.1111/liv.13191. doi: 10.1111/liv.13191 pmid: 27317941
[45]	Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012,82(5):2004-2011. DOI: 10.1016/j.ijrobp.2011.03.019. doi: 10.1016/j.ijrobp.2011.03.019 pmid: 21621346
[46]	Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018,4(5):661-669. DOI: 10.1001/jamaoncol.2017.5847. doi: 10.1001/jamaoncol.2017.5847 pmid: 29543938
[47]	Kim YJ, Jung J, Joo JH, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona Clinic Liver Cancer stage C[J]. Radiother Oncol, 2019,141:95-100. DOI: 10.1016/j.radonc.2019.08.009. doi: 10.1016/j.radonc.2019.08.009 pmid: 31506181
[48]	Lee IJ, Chung JW, Kim HC, et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors[J]. J Vasc Interv Radiol, 2009,20(1):22-29. DOI: 10.1016/j.jvir.2008.09.030. doi: 10.1016/j.jvir.2008.09.030
[49]	Rim CH, Kim CY, Yang DS, et al. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review[J]. Radiother Oncol, 2018,129(1):123-129. DOI: 10.1016/j.radonc.2018.02.030. doi: 10.1016/j.radonc.2018.02.030 pmid: 29606524
[50]	Katz AW, Chawla S, Qu Z, et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation[J]. Int J Radiat Oncol Biol Phys, 2012,83(3):895-900. DOI: 10.1016/j.ijrobp.2011.08.032. doi: 10.1016/j.ijrobp.2011.08.032 pmid: 22172906
[51]	O'Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl, 2012,18(8):949-954. DOI: 10.1002/lt.23439. doi: 10.1002/lt.23439 pmid: 22467602
[52]	Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol, 2017,67(1):92-99. DOI: 10.1016/j.jhep.2017.02.022. doi: 10.1016/j.jhep.2017.02.022 pmid: 28257902
[53]	Chang CM, Wei CK, Lee CH, et al. Long-term follow-up of central hepatocellular carcinoma in comparison with non-central hepatocellular carcinoma[J]. Hepatogastroenterology, 2012,59(114):492-495. DOI: 10.5754/hge11361. doi: 10.5754/hge11361 pmid: 21940385
[54]	Wang WH, Wang Z, Wu JX, et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J]. Liver Int, 2015,35(12):2603-2610. DOI: 10.1111/liv.12857. doi: 10.1111/liv.12857 pmid: 25939444
[55]	Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019,37(24):2141-2151. DOI: 10.1200/JCO.18.02184. doi: 10.1200/JCO.18.02184 pmid: 31283409
[56]	Park YJ, Lim DH, Paik SW, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma[J]. J Gastroenterol, 2006,41(11):1099-1106. DOI: 10.1007/s00535-006-1895-x. doi: 10.1007/s00535-006-1895-x
[57]	Zhou LY, Zeng ZC, Fan J, et al. Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors[J]. BMC Cancer, 2014,14:878. DOI: 10.1186/1471-2407-14-878. doi: 10.1186/1471-2407-14-878 pmid: 25421498
[58]	He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy[J]. Cancer, 2009,115(12):2710-2720. DOI: 10.1002/cncr.24300. doi: 10.1002/cncr.24300 pmid: 19382203
[59]	Jiang W, Zeng ZC, Zhang JY, et al. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma[J]. Clin Exp Metastasis, 2012,29(3):197-205. DOI: 10.1007/s10585-011-9442-4. doi: 10.1007/s10585-011-9442-4 pmid: 22173728
[60]	Park Y, Kim KS, Kim K, et al. Nomogram prediction of survival in patients with brain metastases from hepatocellular carcinoma treated with whole-brain radiotherapy: a multicenter retrospective study[J]. J Neurooncol, 2015,125(2):377-383. DOI: 10.1007/s11060-015-1926-7. doi: 10.1007/s11060-015-1926-7 pmid: 26342711
[61]	Wang MH, Ji Y, Zeng ZC, et al. Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume[J]. Int J Radiat Oncol Biol Phys, 2010,76(2):467-476. DOI: 10.1016/j.ijrobp.2009.01.057. doi: 10.1016/j.ijrobp.2009.01.057 pmid: 19406586
[62]	Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma[J]. Radiother Oncol, 2014,111(3):412-417. DOI: 10.1016/j.radonc.2014.05.002. doi: 10.1016/j.radonc.2014.05.002
[63]	Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication[J]. Int J Radiat Oncol Biol Phys, 2010,78(4):1073-1080. DOI: 10.1016/j.ijrobp.2009.09.009. doi: 10.1016/j.ijrobp.2009.09.009 pmid: 20207492
[64]	Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S94-S100. DOI: 10.1016/j.ijrobp.2009.06.092. doi: 10.1016/j.ijrobp.2009.06.092 pmid: 20171524
[65]	Koay EJ, Owen D, Das P. Radiation-induced liver disease and mo-dern radiotherapy[J]. Semin Radiat Oncol, 2018,28(4):321-331. DOI: 10.1016/j.semradonc.2018.06.007. doi: 10.1016/j.semradonc.2018.06.007 pmid: 30309642
[66]	Hu Y, Zhou YK, Chen YX, et al. 4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]. Med Phys, 2016,43(7):4335. DOI: 10.1118/1.4953190. doi: 10.1118/1.4953190 pmid: 27370148
[67]	中华学会放射肿瘤学分会. 2016年原发性肝癌放疗共识[J]. 中华放射肿瘤学杂志, 2016,25(11):1141-1150. DOI: 10.3760/cma.j.issn.1004-4221.2016.11.001. doi: 10.3760/cma.j.issn.1004-4221.2016.11.001
[68]	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华临床感染病杂志, 2019,12(6):401-428. DOI: 10.3760/cma.j.issn.1674-2397.2019.06.001.

观测指标	评分
观测指标	1	2	3
肝性脑病(期别)	0	1~2	3~4
腹腔积液	无	少量	中等量
白蛋白(g/L)	>35	28~35	<28
凝血酶原时间延长(秒)	<4	4~6	>6
总胆红素(μmol/L)	<34	34~50	>50

分期	T	N	M
ⅠA	T_1a	N₀	M₀
ⅠB	T_1b	N₀	M₀
Ⅱ	T₂	N₀	M₀
ⅢA	T₃	N₀	M₀
ⅢB	T₄	N₀	M₀
ⅣA	任何T	N₁	M₀
ⅣB	任何T	任何N	M₁

中国原发性肝细胞癌放射治疗指南(2020年版)

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 68

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[14]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[15]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.